E. Ohman J or Asset Management AB Sells 11,292 Shares of Thermo Fisher Scientific Inc. $TMO

E. Ohman J or Asset Management AB decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 93,069 shares of the medical research company’s stock after selling 11,292 shares during the period. Thermo Fisher Scientific comprises approximately 1.3% of E. Ohman J or Asset Management AB’s portfolio, making the stock its 13th biggest holding. E. Ohman J or Asset Management AB’s holdings in Thermo Fisher Scientific were worth $53,929,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. JPL Wealth Management LLC bought a new stake in Thermo Fisher Scientific during the third quarter worth about $28,000. Highline Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after acquiring an additional 33 shares during the period. Capital A Wealth Management LLC increased its stake in Thermo Fisher Scientific by 825.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after acquiring an additional 66 shares during the last quarter. Cloud Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $31,000. Finally, Howard Hughes Medical Institute bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at $33,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.8%

Shares of TMO opened at $478.29 on Tuesday. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The firm has a market cap of $177.67 billion, a P/E ratio of 26.96, a PEG ratio of 2.74 and a beta of 0.96. The stock’s 50 day moving average is $540.67 and its two-hundred day moving average is $548.27. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter last year, the company earned $6.10 EPS. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th will be paid a $0.47 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.60%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent research reports. Wells Fargo & Company set a $683.00 target price on Thermo Fisher Scientific in a research report on Friday, January 30th. Barclays increased their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price on the stock in a research report on Sunday, December 7th. Finally, TD Cowen dropped their price target on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $633.68.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.